EMA accepts Kyprolis® marketing authorization application for the treatment of relapsed myeloma

Amgen and it’s subsidiary Onyx Pharmaceuticals Inc., have announced that the European Medicines Agency (EMA) has accepted their application for the marketing authorization of Kyprolis┬« (carfilzomib) as a treatment for relapsed myeloma patients who have received at least one previous line of treatment. The application, based on data from the Phase III ASPIRE trial comparing…

Details